Kasper Fangel

Nominated Board Member and Audit Committee Chair

Therapeutic Areas

Drug	Indication	Phase
Tralokinumab (Lifecycle Management)	Atopic Dermatitis	Approved/Commercial
Pipeline Assets	Underserved Dermatological Diseases	Not Specified (Early to Late-stage)